L. V. Brylev

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The “Sovet” post-marketing observational program was started in 2011. A total of 69 patients with the remitting form of multiple sclerosis (MS) treated with the second-generation DMD natalizumab (NZ) were studied. NZ infusions were given over 1 h every four weeks for 12 months. Treatment produced significant reductions in the frequency of exacerbations of(More)
Motor neuron disease (MND), or amyotrophic lateral sclerosis, is a fatal neurodegenerative disorder characterized by a progressive loss of motor neurons in the spinal cord and the brain. Several angiogenic and neurogenic growth factors, such as the vascular endothelial growth factor (VEGF), angiogenin (ANG), insulin-like growth factor (IGF) and others, have(More)
Amyotrophic lateral sclerosis (ALS) is a continuously progressing neurodegenerative disease that is characterized by selective damage to motoneurons in the neocortex, brainstem, and spinal cord. The general opinion is that sporadic ALS is a multifactor and multigene disease. Realization of its genetic predisposition is determined by environmental factors.(More)
  • 1